Follicular Lymphoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
View More
Dr Casulo discusses the role that observation plays in the treatment of patients with FL.
View More
Peter Martin, MD, discusses recent advancements in the treatment of patients with EZH2-positive FL.
View More
Peter Martin, MD, provides an overview of 2 clinical studies that explored the prognostic value and involvement of PET/CT status in patients with FL.
View More
Peter Martin, MD, discussed the findings and clinical significance of the SAKK 35/15 clinical trial.
View More
Sattva Neelapu, MD, discusses early results from the ALPHA study suggesting that ALLO-501 and ALLO-647 are safe and may be effective in LBCL and FL.
View More
Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.
View More
John Allan, MD, explains the impact the COVID-19 pandemic has had on the treatment of patients with follicular lymphoma and other indolent lymphomas.
View More
Nathan Fowler, MD, discusses the results of of phase 2 study that evaluated the activity and safety of ibrutinib in combination with rituximab in untreated FL.
View More
Stay in the know.
OncNet Newsletter